

## **Astellas Announces Changes to Representative Director and Audit & Supervisory Board Member**

Tokyo, April 27, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that, at a meeting of its Board of Directors held today, it decided on the following changes to the Representative Director and Audit & Supervisory Board Member. The changes to Audit & Supervisory Board Member are subject to the final approval by the Ordinary General Meeting of Shareholders scheduled on June 20, 2016.

### **(1) Change of Representative Director**

- **Representative Director to be retired**

Masafumi Nogimori            (Current) Representative Director and Chairman

Effective date of the change: June 20, 2016

Reason for the change: Mr. Nogimori has committed the company as a representative director and decided to hand over the duties to the current management for the company’s future growth as he judged that it would be appropriate timing.

### **(2) Changes of Audit & Supervisory Board Member**

- **Candidates of Audit & Supervisory Board Member**

Audit & Supervisory Board Member	Hiroko Sakai
Outside Audit & Supervisory Board Member	Noriyuki Uematsu

- **Audit & Supervisory Board Members to be retired**

Audit & Supervisory Board Member	Go Otani
Outside Audit & Supervisory Board Member	Shigeru Nishiyama

**(3) The Board of Directors and the Audit & Supervisory Board as from June 20, 2016  
(planned)**

● **Board of Directors**

Yoshihiko Hatanaka (Representative Director, President and Chief Executive Officer)

Yoshirou Miyokawa (Representative Director, Executive Vice President and Chief Administrative Officer & Chief Compliance Officer)

Yutaka Kase (Outside Director)

Hironobu Yasuda (Outside Director)

Etsuko Okajima (Outside Director)

Yoshiharu Aizawa (Outside Director)

● **Audit & Supervisory Board**

Tomokazu Fujisawa (Audit & Supervisory Board Member)

Hiroko Sakai (Audit & Supervisory Board Member)

Toshiko Oka (Outside Audit & Supervisory Board Member)

Hitoshi Kanamori (Outside Audit & Supervisory Board Member)

Noriyuki Uematsu (Outside Audit & Supervisory Board Member)

**About Astellas**

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at [www.astellas.com/en](http://www.astellas.com/en).

###

Contacts for inquiries or additional information
--

Astellas Pharma Inc.
----------------------

Corporate Communications
--------------------------

TEL: 03-3244-3201 FAX: 03-5201-7473
-------------------------------------

<a href="http://www.astellas.com/en">http://www.astellas.com/en</a>
---